Literature DB >> 25583017

Prognostic indicators in well-differentiated thyroid carcinoma when controlling for stage and treatment.

Kaelyn A Krook1, Stacey A Fedewa, Amy Y Chen.   

Abstract

OBJECTIVES/HYPOTHESIS: The incidence of thyroid carcinoma is rising. Few studies have examined patient characteristics that influence survival when adjusting for treatment and tumor stage/extent. STUDY
DESIGN: Retrospective analysis was performed using the Surveillance Epidemiology and End Results registry data among patients diagnosed with well-differentiated thyroid (WDT) carcinoma during 1988-2009.
METHODS: Kaplan-Meir survival curves were used to estimate 5- and 10-year cause-specific and overall survival differences by sociodemographics, clinical characteristics, and treatment. Multivariate Cox proportional hazard models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs).
RESULTS: A total of 83,985 patients were identified with WDT carcinoma. Blacks had higher hazard of death at 5 years (HR, 1.67; 95% CI, 1.42-1.96) and 10 years (HR, 1.57; 95% CI, 1.37-1.80) when compared to Caucasians, but there were no significant differences in cause-specific deaths. Hispanics had higher overall and cause-specific 5-year and 10-year hazard of death (5-year cause-specific: HR, 1.56; 95% CI, 1.23-1.99). Age was the most significant predictor of cause-specific and overall survival, with risk increasing in a nonlinear fashion. After age 45 years, the HR for 5- and 10-year cause-specific survival rose drastically, reaching an HR of 153 for individuals aged 85 years and older (HR, 153.45; 95% CI, 97.84-240.67).
CONCLUSIONS: Age was the strongest factor associated with WDT cancer in our study. African Americans had worse overall survival, although only Hispanics had a significantly worse cause-specific survival. These factors should be taken into account in counseling patients and treatment planning.
© 2014 The American Laryngological, Rhinological and Otological Society, Inc.

Entities:  

Keywords:  Thyroid carcinoma; outcomes; race; survival

Mesh:

Year:  2015        PMID: 25583017     DOI: 10.1002/lary.25017

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  7 in total

1.  Trends and Predictors of Chemotherapy Use among Thyroid Cancer Patients in the National Cancer Database (2004-2013).

Authors:  Stacey A Fedewa; Ahmedin Jemal; Amy Y Chen
Journal:  Eur Thyroid J       Date:  2016-10-21

2.  Racial/ethnic differences in thyroid cancer incidence in the United States, 2007-2014.

Authors:  Kristin S Weeks; Amanda R Kahl; Charles F Lynch; Mary E Charlton
Journal:  Cancer       Date:  2018-01-16       Impact factor: 6.860

3.  Downregulated expression of TSHR is associated with distant metastasis in thyroid cancer.

Authors:  Tianrun Liu; Qianqian Men; Xuan Su; Weichao Chen; Lan Zou; Qiuli Li; Ming Song; Dian Ouyang; Yanfeng Chen; Zhaoqu Li; Xiaoyan Fu; Ankui Yang
Journal:  Oncol Lett       Date:  2017-10-03       Impact factor: 2.967

Review 4.  The Adverse Effect of Hypertension in the Treatment of Thyroid Cancer with Multi-Kinase Inhibitors.

Authors:  Ole Vincent Ancker; Markus Wehland; Johann Bauer; Manfred Infanger; Daniela Grimm
Journal:  Int J Mol Sci       Date:  2017-03-14       Impact factor: 5.923

5.  Nodal disease predicts recurrence whereas other traditional factors affect survival in a cohort of South African patients with differentiated thyroid carcinoma.

Authors:  B Robertson; M Parker; L Shepherd; E Panieri; L Cairncross; F Malherbe; I L Ross; F Omar; A Hunter
Journal:  Cancers Head Neck       Date:  2018-11-19

6.  Thyroid cancer incidence trend and association with obesity, physical activity in the United States.

Authors:  Biaoyou Chen; Zhaomin Xie; Xuwei Duan
Journal:  BMC Public Health       Date:  2022-07-12       Impact factor: 4.135

7.  Overall Survival of Papillary Thyroid Carcinoma Patients: A Single-Institution Long-Term Follow-Up of 5897 Patients.

Authors:  Yasuhiro Ito; Akira Miyauchi; Minoru Kihara; Mitsuhiro Fukushima; Takuya Higashiyama; Akihiro Miya
Journal:  World J Surg       Date:  2018-03       Impact factor: 3.352

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.